Human coronaviruses are significant pathogens of the respiratory tract, with their global impact underscored by the recent SARS-CoV-2 pandemic. This crisis has emphasized the urgent need for broad-spectrum antiviral agents targeting coronaviruses. Ideally, such therapeutics should employ novel mechanisms of action to complement existing approved drugs, thereby enabling combination therapies that enhance the genetic barrier to resistance. Coronaviruses helicase (Nsp13) has emerged as a particularly attractive target as essential for the viral life cycle. Its conservation across coronaviruses suggests that nsp13 inhibitors could offer broad-spectrum antiviral activity. In this study, we present preliminary results of in-house molecules, selected with an in-silico screening as potential pan-helicases inhibitors and subsequently optimized. The most promising compound showed an EC50 value of 6.5 μM in VeroE6-GFP and 14.5 μM in A549 dual cells against SARS-CoV-2 and no toxicity up to 100 μM. Also, it was tested on both the SARS-CoV-2 nsp13 unwinding and ATPase associated biochemical functions, proving an inhibition of the enzyme activity in the low micromolar range. Broad-spectrum activity was evaluated against human betacoronavirus OC43 (HCoV-OC43) and alphacoronavirus 229E (HCoV-229E). Given that HCoV-OC43 serves as a suitable surrogate for SARS-CoV-2, we used it for mode-of-action studies in HeLa cells. Time-of-drug-addition assays proved an inhibition in a timeframe that is in accordance with the nsp13 target, while no entry neither inactivation effect was detected. Finally, the compound showed an inhibition of HCoV-OC43 replication and no toxicity in primary upper airway epithelial cells. These encouraging results pave the way for further lead optimization
IDENTIFICATION AND CHARACTERIZATION OF A NEW BROAD-SPECTRUM HELICASE INHIBITOR AGAINST HUMAN CORONAVIRUSES
Roberta EmmoloPrimo
;Giulia Atzeni;Antonio Lupia;Erica Sanna;Simona Distinto;Elias Maccioni;Enzo Tramontano;Angela Corona
Ultimo
2026-01-01
Abstract
Human coronaviruses are significant pathogens of the respiratory tract, with their global impact underscored by the recent SARS-CoV-2 pandemic. This crisis has emphasized the urgent need for broad-spectrum antiviral agents targeting coronaviruses. Ideally, such therapeutics should employ novel mechanisms of action to complement existing approved drugs, thereby enabling combination therapies that enhance the genetic barrier to resistance. Coronaviruses helicase (Nsp13) has emerged as a particularly attractive target as essential for the viral life cycle. Its conservation across coronaviruses suggests that nsp13 inhibitors could offer broad-spectrum antiviral activity. In this study, we present preliminary results of in-house molecules, selected with an in-silico screening as potential pan-helicases inhibitors and subsequently optimized. The most promising compound showed an EC50 value of 6.5 μM in VeroE6-GFP and 14.5 μM in A549 dual cells against SARS-CoV-2 and no toxicity up to 100 μM. Also, it was tested on both the SARS-CoV-2 nsp13 unwinding and ATPase associated biochemical functions, proving an inhibition of the enzyme activity in the low micromolar range. Broad-spectrum activity was evaluated against human betacoronavirus OC43 (HCoV-OC43) and alphacoronavirus 229E (HCoV-229E). Given that HCoV-OC43 serves as a suitable surrogate for SARS-CoV-2, we used it for mode-of-action studies in HeLa cells. Time-of-drug-addition assays proved an inhibition in a timeframe that is in accordance with the nsp13 target, while no entry neither inactivation effect was detected. Finally, the compound showed an inhibition of HCoV-OC43 replication and no toxicity in primary upper airway epithelial cells. These encouraging results pave the way for further lead optimizationI metadati presenti in IRIS UNICA sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono protetti da diritto d'autore, salvo diversa indicazione.



